Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

• DOI: 10.1097/igc.0b013e3182070f17
• Publication Date: 2011-01-26T04:57:47Z
• Authors: Gordon John Samps...; Ignace Vergote; Elizabeth Eisenhauer; Eric Pujade-Lauraine; Michael Quinn; Tate Thigpen; Andreas du Bois; Gunnar Kristensen; Anders Jakobsen; Satoru Sagae; Kathryn Greven; Mahesh Parmar; Michael Friedlander; Andres Cervantes; Jan Vermorken
• Keywords: Gynecologic cancer

The Gynecological Cancer Intergroup (GCIG) has previously reached consensus regarding the criteria that should be used in clinical trial protocols to define progression-free survival after first-line therapy as well response treatment recurrent disease using serum marker CA 125 and specified situations where these used. However, publications did not include detailed definitions, nor were they written accommodate new version of Response Evaluation Criteria In Solid Tumors (RECIST) (version 1.1) now available. Thus, we recommend definitions described later detail are incorporated into maintain consistency. for defining progression acceptable trials have since been validated (Pujade-Lauraine, personal communication, 2010). GCIG requests data from all made available centers so continual validation improvement can accomplished. These developed analyzing patients receiving cytotoxic chemotherapy yet molecular targeting agents.